STOCK TITAN

Cerus (CERS) Stock Price, News & Analysis

CERS NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
47 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+34% close of May 1, 2026
1-year change
+24.2% closing prices, November 17, 2025 to November 17, 2026
1-month change
-12.8% closing prices, October 16, 2026 to November 17, 2026

Company Description

Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused on blood transfusion safety. According to company disclosures, Cerus is dedicated solely to safeguarding the world’s blood supply and operates in a single business segment centered on blood safety. The company develops and supplies technologies designed to provide pathogen-protected blood components for use by blood centers, hospitals, and patients who rely on safe blood.

Cerus is headquartered in Concord, California and its shares trade on the Nasdaq Stock Market under the symbol CERS. The company’s activities fit within the surgical and medical instrument manufacturing industry, with a clear emphasis on transfusion medicine and pathogen reduction technologies for blood components.

Core products and technologies

The company’s principal technology platform is the INTERCEPT Blood System. Cerus states that the INTERCEPT Blood System for platelets and plasma is available globally and is the only pathogen reduction system with both CE mark and U.S. Food and Drug Administration (FDA) approval for these two blood components. The system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, including viruses, bacteria, and parasites, in platelet and plasma components.

In the United States, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex (IFC). Cerus describes IFC as a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The company reports growing hospital demand for IFC in the U.S. and increasing revenue contributions from this product.

Cerus also reports that the INTERCEPT red blood cell (RBC) system is under regulatory review in Europe and in late-stage clinical development in the United States. The company’s disclosures reference Phase 3 clinical work, including the RedeS trial, to evaluate red blood cells prepared with the INTERCEPT Blood System for patients requiring RBC transfusion for acute and chronic anemia.

Business model and revenue sources

According to Cerus, the firm operates in a single segment focused on blood safety and generates revenue primarily from product sales related to its INTERCEPT systems and associated blood components. Company communications also describe government contract revenue associated with research and development activities, including funding related to the INTERCEPT RBC program, next-generation pathogen reduction technology for whole blood, and development of lyophilized IFC.

Cerus reports product revenue from INTERCEPT platelet and plasma systems and from IFC. The company has highlighted growth in global platelet sales and U.S. IFC sales, and has discussed product revenue guidance ranges in its financial updates. Government contracts, including agreements with agencies such as the U.S. Department of Defense and BARDA, are described as supporting development programs for RBC pathogen reduction, whole-blood applications, and lyophilized IFC.

Geographic reach and customers

The company states that it sells its INTERCEPT platelet and plasma systems in the United States, Europe, Commonwealth of Independent States countries, the Middle East, and selected countries in other regions. Cerus describes its customer base as including blood centers and hospitals, which use INTERCEPT-treated components in transfusion practice. Company communications reference blood centers and hospitals in multiple countries and note that Cerus supports blood centers in their efforts to ensure blood safety and availability.

Cerus has also announced agreements and collaborations that relate to distribution and adoption of its products. For example, the company reported a group purchasing agreement with Blood Centers of America covering the INTERCEPT product line, with the aim of expanding access to pathogen reduction technology for platelets, plasma, and IFC across member blood centers and their hospital customers.

Research, development, and clinical programs

Cerus describes ongoing investment in research and development to advance its pathogen reduction technologies. The company has highlighted several key areas:

  • Clinical development of the INTERCEPT RBC system, including the U.S. Phase 3 RedeS trial evaluating safety and efficacy in anemia patients requiring RBC transfusions.
  • Development of INT200, a next-generation LED-based illumination device used in conjunction with INTERCEPT treatments, with plans for regulatory submissions described in company announcements.
  • Work on next-generation pathogen reduction technology for whole blood, supported in part by government contract funding.
  • Development of lyophilized INTERCEPT Fibrinogen Complex (LyoIFC) intended as a room-temperature, shelf-stable product for use in environments where refrigeration is limited or not feasible.

Company communications also reference scientific presentations and abstracts related to INTERCEPT technologies at professional meetings, including studies on platelets, plasma, cryoprecipitated fibrinogen, and red blood cells. These materials focus on aspects such as bacterial inactivation, functional properties of treated components, and clinical and operational considerations in transfusion practice.

Role in transfusion medicine

Cerus positions itself as a company focused on enhancing blood safety and availability. Its disclosures emphasize pathogen inactivation as a proactive approach to reducing transfusion-transmitted infections in platelets and plasma, and the use of IFC to address bleeding associated with fibrinogen deficiency. The company notes that its technologies are used to produce pathogen-protected blood components and that it collaborates with blood centers, hospitals, and governmental entities to support adoption and further development of these products.

Regulatory and industry context

Cerus’ products operate within regulated medical and transfusion markets. The company notes that the INTERCEPT Blood System for platelets and plasma has CE mark and FDA approval, that the INTERCEPT Blood System for Cryoprecipitation is FDA-approved for IFC production in the U.S., and that the INTERCEPT RBC system is under regulatory review in Europe and in late-stage clinical development in the U.S. Company communications also reference external recommendations, such as a German National Blood Advisory Committee position paper that includes pathogen inactivation as a measure to enhance platelet transfusion safety, and note that INTERCEPT platelets are approved and commercially available in Germany.

Stock and corporate governance

Cerus Corporation is incorporated in Delaware and files periodic reports with the U.S. Securities and Exchange Commission. The company has reported changes in board leadership through Form 8-K filings, including the appointment of its president and chief executive officer as chair of the board and the designation of a lead independent director. These filings, along with earnings-related 8-Ks, provide investors with updates on financial results and corporate governance matters.

Stock Performance

$1.90
+2.15%
+0.04
Last updated: November 17, 2026 at 16:00
+24.2%
Performance 1 year
$383.7M

Cerus (CERS) closed at $1.90 on November 17, 2026. Over the past 12 months, the price has gained 24.2%.

See what a $1,000 investment in CERS would be worth today

Average down calculator for CERS

CERS Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Cerus generated $233.8M in revenue in FY2025, operating income reached -$8.7M (-3.7% operating margin), and net income was -$15.6M, reflecting a -6.7% net profit margin. Diluted earnings per share stood at -$0.08. The company generated $4.8M in operating cash flow. The current ratio was 1.73, measuring current assets divided by current liabilities.

$233.8M
Revenue (FY2025)
-$15.6M
Net Income (FY2025)
$4.8M
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

Craig-Hallum Conference

Management to attend Craig-Hallum Alpha Select Conference in New York City on Nov 17; hosting one-on-one investor meetings.
DEC
2026
December 2026 Corporate

CHRO appointment

Betsy Jensen appointed Chief Human Resources Officer, appointment effective December 2026; no webcast or location provided.
DEC
01
December 1, 2026 Marketing

Citi Global Healthcare Conference

One-on-one investor meetings at Citi's 2026 Global Healthcare Conference in Miami on Dec 1; management attending, no webcast.
DEC
02
December 2, 2026 Marketing

Piper Sandler Healthcare Conference

One-on-one investor meetings at Piper Sandler 38th Annual Healthcare Conference in New York on Dec 2; management attending.

Cerus has 4 upcoming scheduled events. The next event, "Craig-Hallum Conference", is scheduled for November 17, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the CERS stock price.

Short Interest History

Last 12 Months

Short interest in Cerus (CERS) currently stands at 14.6 million shares, down 12.0% from the previous reporting period, representing 7.5% of the float. Since November 2025, short interest has increased by 150.6%.

Days to Cover History

Last 12 Months

Days to cover for Cerus (CERS) currently stands at 8.2 days, down 12.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 83.4%. Across the settlements charted above, it has ranged from 3.6 to 16.6 days.

CERS Company Profile & Sector Positioning

Cerus (CERS) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CERS often look at related companies in the same sector, including Brainsway Ltd. (BWAY), 908 Devices Inc. (MASS), Avita Medical, Inc. (RCEL), Viemed Healthcare, Inc. (VMD), and Treace Medical Concepts, Inc. (TMCI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CERS's relative position within its industry.

Frequently Asked Questions

The current stock price of Cerus (CERS) is $1.90 as of November 17, 2026.

The market cap of Cerus (CERS) is approximately $383.7M. Learn more about what market capitalization means .

The FY2025 revenue of Cerus (CERS) is $233.8M, from its most recent completed fiscal year.

The FY2025 net income of Cerus (CERS) is -$15.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Cerus (CERS) is -$0.08 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Cerus (CERS) is $4.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Cerus (CERS) is -6.7% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Cerus (CERS) is -3.7% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Cerus (CERS), current assets divided by current liabilities, was 1.73 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Cerus (CERS) is -$8.7M for FY2025, its most recent completed fiscal year. Learn about operating income.

Cerus Corporation operates in the biomedical products and surgical and medical instrument manufacturing space, with a specific focus on blood transfusion safety and pathogen reduction technologies for blood components.

Cerus states that it is dedicated solely to safeguarding the world’s blood supply. Its main focus is developing and supplying technologies, such as the INTERCEPT Blood System, that provide pathogen-protected blood components for blood centers and hospitals.

According to Cerus, the INTERCEPT Blood System is used for platelets and plasma, and in the U.S. for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex). The company is also developing and seeking approvals for an INTERCEPT red blood cell system.

Cerus Corporation reports that it is headquartered in Concord, California.

Cerus describes INTERCEPT Fibrinogen Complex as a pathogen-reduced cryoprecipitated fibrinogen complex approved in the U.S. as a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

The company states that it sells its INTERCEPT platelet and plasma systems in the United States, Europe, Commonwealth of Independent States countries, the Middle East, and selected countries in other regions.

Cerus reports product revenue from sales of INTERCEPT-related products, including platelets, plasma, and IFC, and government contract revenue associated with research and development activities for programs such as the INTERCEPT RBC system, whole-blood pathogen reduction, and lyophilized IFC.

Cerus reports that the INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the United States, supported by Phase 3 clinical trials such as the RedeS study.

INT200 is described by Cerus as a next-generation LED-based illumination device used in its pathogen reduction processes. The company has highlighted development work and anticipated regulatory submissions for this device.

LyoIFC is lyophilized Pathogen Reduced Cryoprecipitated Fibrinogen Complex. Cerus, with funding from the U.S. Department of Defense, is developing LyoIFC as a room-temperature, shelf-stable product intended for use in settings where refrigeration is limited or not feasible, such as austere environments.